Racehorse Blood Study Targets Doping And Cardiac Risk

Racing regulators may soon have a new tool between the routine veterinary exam and a confirmed medication positive: a detailed picture of how a healthy racehorse's blood should respond to competition. Researchers in Minnesota are collecting paired samples from Thoroughbreds, Quarter Horses and Standardbreds to establish post-race reference ranges for cardiac, thyroid, electrolyte and muscle markers. The goal is not to replace drug testing, but to identify horses whose physiological response deserves a closer look.

The project grew from observations at Canterbury Park and Running Aces, where some horses reportedly retained unusually high heart rates after racing. Minnesota Racing Commission chief veterinarian Lynn Hovda and University of Minnesota researcher Sian Durward-Akhurst helped develop a study that samples horses roughly 90 minutes before a race and again within an hour afterward. About 30 horses of each breed were included in the initial collection, with an eventual target of approximately 40 per breed.

That timing matters. Cardiac troponin I can enter the bloodstream after heart-muscle injury, but strenuous exercise can also affect its concentration. Thyroid hormones present a similar interpretive problem: an elevated reading could reflect supplementation, yet it cannot identify a prohibited substance or prove intent. By comparing each horse with its own pre-race baseline, investigators hope to separate an expected exertional response from a potentially meaningful abnormality. The samples remain frozen, with initial reference ranges expected in spring 2027.

New Mexico has already offered a glimpse of how the approach might work in practice. The New Mexico Racing Commission screened Quarter Horse qualifiers for the All American Futurity, Derby and Oaks using thyroid-hormone and cardiac-troponin testing. Six horses were placed on the veterinarian's list after elevated readings, and one was not cleared to compete. Those results were not drug positives; they were veterinary signals that prompted additional scrutiny.

For handicappers, the important distinction is that this is not a new angle for identifying a “doped” horse on a past-performance page. A high troponin result could indicate cardiac injury or simply follow a hard race, while thyroid abnormalities require clinical context. The immediate value is welfare: a regulator can flag poor recovery and decide whether the next step should be an examination, cardiac monitoring or a period away from competition.

The longer-term implications reach into racing's most difficult medical question: exercise-associated sudden death. A University of Minnesota thesis examining Thoroughbred cases identified eight genomic regions associated with the condition and reported potentially relevant variants in genes including TNNT2, TRDN and CACNA1D, but those findings remain candidates for further investigation rather than a predictive test. The university's research record describes the work as an effort to identify genetic contributors to exercise-induced arrhythmia and sudden death.

That caution should guide the bloodwork project as well. Its first assignment is simply to define normal under racing conditions, a more useful standard than reference ranges built from lightly exercised teaching horses. If the Minnesota data ultimately reveal consistent links among abnormal recovery, cardiac biomarkers, medication patterns and later performance or health events, regulators will have a stronger basis for targeted investigation. Until then, the science offers an early warning system—not a shortcut around laboratory confirmation.

Comments

No comments yet. Why don’t you start the discussion?

Talkback